Cited 35 times in
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경래 | - |
dc.contributor.author | 남지선 | - |
dc.contributor.author | 박종숙 | - |
dc.contributor.author | 안철우 | - |
dc.contributor.author | 유정선 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 조민호 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2014-12-20T16:39:06Z | - |
dc.date.available | 2014-12-20T16:39:06Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0804-4643 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/93118 | - |
dc.description.abstract | OBJECTIVE: Osteoprotegerin (OPG) acts as an important regulatory molecule in atherosclerosis. Recent studies report that thiazolidinediones could affect OPG expression. We investigated the relationship between OPG and inflammatory cytokines and the effects of pioglitazone (a PPARγ (PPARG) agonist) versus metformin on serum OPG levels in type 2 diabetic patients. DESIGN AND METHODS: Sixty-seven type 2 diabetic patients were included in this study. They were assigned to pioglitazone (15 mg/day, n=34) or metformin (1000 mg/day, n=33) during 24 weeks. Various anthropometric and metabolic parameters, OPG, interleukin 6 (IL6), C-reactive protein (CRP), adiponectin, and homeostasis model assessment of insulin resistance (HOMA-IR), were measured at baseline and at 6 months of treatment. RESULTS: Serum OPG levels correlated significantly with fasting plasma glucose (FPG), HbAlc, HOMA-IR, IL6, and CRP, and inversely correlated with adiponectin after adjusting for age (P<0.05). Multiple regression analysis showed that FPG, HbAlc, and adioponectin were independently correlated with OPG level. After 6 months of treatment, the reduction in FPG and HbAlc levels was similar between the two groups. Pioglitazone treatment significantly increased body mass index (P<0.05) and waist circumference (P<0.05) and decreased triglycerides (P<0.05) and HOMA-IR (P<0.01). The adiponectin concentration was increased (P<0.05), and OPG and CRP levels were decreased in the pioglitazone group (P<0.05), but were unchanged in the metformin group. The changes in serum OPG in the pioglitazone group showed significant correlation with changes in FPG, HbAlc, and adiponectin. CONCLUSIONS: In type 2 diabetic patients, pioglitazone decreases OPG levels, and this decrease in OPG levels might be associated with the increase in adiponectin. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 69~74 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF ENDOCRINOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adiponectin/blood | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Blood Glucose/metabolism | - |
dc.subject.MESH | C-Reactive Protein/metabolism | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/blood* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/pharmacology | - |
dc.subject.MESH | Hypoglycemic Agents/therapeutic use* | - |
dc.subject.MESH | Insulin/blood | - |
dc.subject.MESH | Insulin Resistance | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Metformin/therapeutic use | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoprotegerin/blood* | - |
dc.subject.MESH | Thiazolidinediones/pharmacology | - |
dc.subject.MESH | Thiazolidinediones/therapeutic use* | - |
dc.title | Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jong Suk Park | - |
dc.contributor.googleauthor | Min Ho Cho | - |
dc.contributor.googleauthor | Ji Sun Nam | - |
dc.contributor.googleauthor | Jeong Seon Yoo | - |
dc.contributor.googleauthor | ChulWoo Ahn | - |
dc.contributor.googleauthor | Bong Soo Cha | - |
dc.contributor.googleauthor | Kyung Rae Kim | - |
dc.contributor.googleauthor | Hyun Chul Lee | - |
dc.identifier.doi | 10.1530/EJE-10-0875 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00294 | - |
dc.contributor.localId | A01268 | - |
dc.contributor.localId | A02270 | - |
dc.contributor.localId | A02499 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03819 | - |
dc.contributor.localId | A03996 | - |
dc.contributor.localId | A01660 | - |
dc.relation.journalcode | J00819 | - |
dc.identifier.eissn | 1479-683X | - |
dc.identifier.pmid | 20961967 | - |
dc.contributor.alternativeName | Kim, Kyung Rae | - |
dc.contributor.alternativeName | Nam, Ji Sun | - |
dc.contributor.alternativeName | Park, Jong Suk | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.alternativeName | Yoo, Jeong Seon | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Cho, Min Ho | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Rae | - |
dc.contributor.affiliatedAuthor | Nam, Ji Sun | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Yoo, Jeong Seon | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cho, Min Ho | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Park, Jong Suk | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 164 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 69 | - |
dc.citation.endPage | 74 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF ENDOCRINOLOGY, Vol.164(1) : 69-74, 2011 | - |
dc.identifier.rimsid | 28041 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.